ProShares Trust has filed its latest NPORT-P report, providing insights into its financial performance and investment strategies. This filing is significant as it outlines the current status of the ProShares UltraShort Nasdaq Biotechnology fund, which has seen considerable fluctuations in its returns.

The report, filed on October 28, 2026, reveals that the fund's total assets stand at approximately $2.44 million, with net assets of about $1.87 million. The filing indicates that the fund has faced challenges, with recent monthly returns reflecting volatility. For instance, the fund reported a return of -17.55% in one month, followed by a slight recovery of 3.24%, and another decline of -19.43% in subsequent months.

Background

ProShares Trust is an investment entity based in Bethesda, Maryland. The company focuses on providing exchange-traded funds (ETFs) that allow investors to gain exposure to various market segments. The firm is known for its innovative investment strategies, particularly in leveraged and inverse ETFs, which are designed to amplify returns or provide hedging opportunities.

The company has a history of filing various forms with the SEC, including recent NPORT-P submissions on October 28, 2026. This filing is part of a series of reports that provide transparency on the fund's performance and investment strategy.

What the Filing Says

The NPORT-P filing details the financial metrics of the ProShares UltraShort Nasdaq Biotechnology fund. It highlights total liabilities of approximately $570,993, leading to net assets of $1,871,310. The report also lists a total cash amount not reported in the current liabilities, which stands at approximately $917,948.

In terms of investment performance, the fund's returns have been volatile, with the filing stating, "monthly total returns" reflecting significant fluctuations. The report provides detailed insights into various categories of investments, including equity contracts and total return swaps.

Impact

This filing may affect various stakeholders, including investors, financial analysts, and competitors in the investment industry. Investors will be closely monitoring the fund's performance and may adjust their strategies based on the reported volatility. Financial analysts will likely analyze the data to gauge market trends and the fund's potential future performance.

Additionally, competitors in the biotechnology investment sector may need to reassess their strategies in light of ProShares Trust's performance. The fluctuations reported could indicate broader market trends, prompting other firms to adapt their investment approaches.

What's Next

The filing does not specify what happens next for ProShares Trust. However, stakeholders will likely await further updates and filings that could provide additional insights into the fund's performance and strategic direction.

For more details, the full filing can be accessed via the SEC's EDGAR database under accession number 0002071691-26-025234.